QuidelOrtho Corporation (QDEL) Fair Value 2026

QDEL · In Vitro & In Vivo Diagnostic Substances ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.9 /10

32 fundamental signals · 9 models active

Value Trap Risk

WARN (52/100)

Quick Summary — As of 2026-07-13, QuidelOrtho Corporation (QDEL) trades at $17.89, approximately 68% below CirclFi’s Bayesian DCF fair value of $56.05. QOC: 6.9/10. Value Trap Risk: 52/100 (WARN). 9/13 models active.

Key Facts

Ticker
QDEL
Price
$17.89
Quality Score
6.9/10
Value Trap Risk
52/100
Models Active
9/13
Last Updated
Strength: First Chicago suggests +452.6% upside with 55% confidence
Risk: Value Trap score of 52 suggests caution despite apparent undervaluation

Valuation Matrix

9 Intrinsic Value Models vs. Current Price ($17.89)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
High Conviction
$56.05 +213.3%
CUCE Ensemble
Low Conviction
$69.47 +288.3%
First Chicago
High Conviction
$98.86 +452.6%
RCMH-DCF
High Conviction
$34.48 +92.7%

Unlock the Full Matrix

Access 5 additional models including ML-RIV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is QuidelOrtho Corporation (QDEL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for QuidelOrtho Corporation. Trading at $17.89 against an estimated intrinsic value of $47.89, 8 of 9 active models flag meaningful upside of +167.7% on average. The most optimistic model, First Chicago, places fair value at $98.86 (+452.6%), while Sentiment SOTP — the most conservative — estimates $15.84 (-11.5%). This +464.1% gap reflects genuine analytical uncertainty about QuidelOrtho Corporation's intrinsic worth.

What Do the Models Say About QDEL?

9 of 13 models are currently active for QDEL. Of these, 8 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates QDEL's intrinsic value at $56.05, implying +213.3% upside from the current price. See which stocks rank higher →

How Does QDEL Rank in In Vitro & In Vivo Diagnostic Substances?

Among 17 In Vitro & In Vivo Diagnostic Substances stocks, QDEL ranks #5 by Quality of Company score. CirclFi's QOC score of 6.9/10 evaluates 32 fundamental signals. A score of 6.9 indicates above-average quality.

QuidelOrtho Corporation operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is QDEL a Value Trap?

CirclFi's Value Trap algorithm assigns QDEL a score of 52/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for QuidelOrtho Corporation. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, QuidelOrtho Corporation scores 6.9 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +464.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every QDEL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across QDEL's 9 active models, average confidence is 39%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy QuidelOrtho Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar In Vitro & In Vivo Diagnostic Substances Stocks Should You Also Analyze?

8 related In Vitro & In Vivo Diagnostic Substances stocks with 13-model coverage

Read investment analysis: IDXX · LNTH · NEOG · ICCC · NTLA

Frequently Asked Questions About QuidelOrtho Corporation

What is QuidelOrtho Corporation's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, QuidelOrtho Corporation (QDEL) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $56.05. The Quality of Company score is 6.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is QDEL overvalued or undervalued right now?

At $17.89, 8 of 9 active models suggest QDEL may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits QuidelOrtho Corporation's business model in In Vitro & In Vivo Diagnostic Substances.

What does a Quality of Company score of 6.9 mean for QDEL?

QuidelOrtho Corporation's QOC of 6.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on QDEL?

CirclFi analyzes QDEL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Is QDEL a value trap in 2026?

QuidelOrtho Corporation's Value Trap score is 52/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on QDEL.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access